REG - Schroders Cap Glbl - Q3 2024 NAV and Continuation Vote Arrangements

Schroders Capital Global Innovation TrustAnnouncement

04/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241204:nRSD6870Oa&default-theme=true

RNS Number : 6870O  Schroders Capital Global Innovation  04 December 2024

Schroders Capital Global Innovation Trust plc

Q3 2024 Quarterly Net Asset Value and Continuation Vote Arrangements

Schroders Capital Global Innovation Trust plc (the "Company") today announces
its net asset value ("NAV") as of 30 September 2024.

Summary

·      As of 30 September 2024, NAV per share stands at 20.14p, a
decrease of 4.0% relative to the NAV per share as of 30 June 2024 (20.99p).

 

·      Performance over the quarter was positively impacted by the
revaluation of Revolut following news of its UK banking licence approval and
secondary share sale providing liquidity for employees at a $45 billion
valuation.

 

·      Performance over the quarter was negatively impacted, as
previously disclosed in the Company's interim report and financial statements
for the six months ended 30 June 2024, by downwards valuations to Ada Health
and Bizongo, and the full write-off of Reaction Engines which entered
administration.

 

·      During the quarter, the Company made £9.5 million of further
realisations of Oxford Nanopore Technologies, benefitting from strong share
price performance.

 

·      The Company made £7.5 million of investments, including a new
investment in "AI Company III"¹, and the final tranche of the initial
investments in "AI Company II"¹ and Life Sciences portfolio company, Araris
Biotech.

·      As of 30 September 2024, the Company had £29.2 million in cash
and money market (sterling liquidity) funds and £8.9 million in liquid public
equity investments(²) to meet the funding requirements of the existing
portfolio and execute the buyback programme.

·      The Company is on target with its share repurchase programme for
2024 in order to meet its 5% commitment for the year. As of 30 September 2024,
the Company had repurchased 35,240,000 shares for cancellation during the
year, with a further 2,760,000  shares repurchased for cancellation as of 31
October 2024.

 

·      The Board has determined, following a shareholder consultation
exercise, to bring forward the continuation vote in order to provide clarity
on the future of the Company at the earliest opportunity.

¹Actual name not disclosed due to confidentiality. ² Excluding BenevolentAI
which is fair value priced by the AIFM.

Performance

The NAV as of 30 September 2024 was £165.6 million, a decrease of 4.9%
compared to the NAV (£174.1 million) as of 30 June 2024. The NAV per share as
of 30 September 2024 was 20.14p, a decrease of 4.0% compared with the NAV per
share (20.99p) as of 30 June 2024. The difference between the NAV and NAV per
share decrease is due to the share buybacks during the period.

 Attribution analysis (£m)                                  Private equity                  Public equity  Money market funds  Cash    Other  NAV
                                                            Life sciences  Venture  Growth
 Fair value as at 30.06.24                                  20.0           35.9     74.5    16.0           25.2                4.8     (2.3)  174.1
 + Investments                                              1.3            6.2      -       -              7.9                 (15.4)  -      -
 - Realisations at value                                    -              -        -       (9.5)          (6.1)               15.6    -      -
 +/- Fair value gains/(losses)                              (0.4)          (3.7)    (7.5)   4.2            0.4                 -       -      (7.0)
 - Repurchase and cancellation of the Company's own shares  -              -        -       -              -                   (0.9)   -      (0.9)
 +/- Costs and other movements                              -              -        -       -              -                   (2.3)   1.7    (0.6)
 Fair value as at 30.09.24                                  20.9           38.4     67.0    10.7           27.4                1.8     (0.6)  165.6

 

The notable detractor from performance over the quarter was in the Company's
growth holdings, which saw a fair value loss of 10.1%, contributing a 4.3%
decrease to the overall NAV. This was primarily due to a fall in value in the
holdings in Bizongo and Ada Health.

The valuation of Bizongo was reduced during the quarter to reflect near-term
growth expectations following a recent restructuring of its business lines.

Ada Health recorded significant revenue growth between 2020 to 2023 and
reached EBITDA level profitability in 2023, driven by new large contract wins.
On this basis, the investment was written up in Q2 2024. However, during Q3,
the business growth outlook has become more uncertain driven by a challenging
market environment, resulting in a downwards valuation during the quarter.

On the positive side, following its strong 2023 financial results released
earlier in the year, Revolut announced two important updates. Firstly, the
company received its UK banking licence with restrictions from the Prudential
Regulation Authority, the regulator responsible for overseeing the UK banking
sector, to complete the build out of their UK banking operations.
Subsequently, the company announced a secondary share sale providing liquidity
for employees at a $45 billion valuation. In November, the company also
announced the significant milestone of surpassing 50 million global customers
in 28 markets - an impressive feat over 9 years.

The Company's venture holdings also saw a fair value loss of 10.3% (net of
capital activity), contributing 2.1% to the overall NAV decrease. This was
mainly driven by Genomics due to a downwards revaluation based on a slight
delay in the commercial rollout.

The life sciences portfolio remained broadly stable during the quarter.

The Company's public equity holdings saw a fair value gain of 26.3% (net of
capital activity), offsetting the overall NAV decline in the private portfolio
by 2.4%. This was driven by Oxford Nanopore Technologies, which, during the
quarter, experienced a share price increase of 69.1%. Oxford Nanopore
Technologies published its half year trading update detailing underlying
year-on-year LSRT revenue growth of 12.4%, lower than the annual target of
20-30%, although in-line with the company's expected phasing, with 2024 and
longer-term guidance unchanged. In August, the company also announced the
completion of an £80 million equity issue led by strategic investor, Novo
Holdings A/S, the investment company responsible for managing the assets and
the wealth of the Novo Nordisk Foundation. No specific use of proceeds was
disclosed, only to strengthen the company's financial position and provide
further headroom to implement the business plan through breakeven in 2027 or
2028.

Foreign Exchange

During the quarter, the fair value of investments denominated in the Euro
(EUR) and US Dollar (USD) were negatively impacted by the appreciation of
British pound sterling (GBP) relative to these currencies.

 

Cash, debt, and net current assets

As of 30 September 2024, the Company held £29.2 million in cash and money
market (sterling liquidity) funds.

Investment activity

Realisations

During the quarter, the Company made realisations of equity positions
totalling £9.5 million, almost exclusively from further reducing the holding
in Oxford Nanopore Technologies.

Investments

During the quarter, the Company made investments totalling £7.5 million. This
comprised of: a new Venture investment of £3.9 million in "AI Company III"
¹, a developer of proprietary generative AI foundational model for software
development; a tranched investment in Araris Biotech, a Swiss oncology biotech
company developing next-generation antibody drug conjugates, as agreed when
the initial investment made in 2022; and the second tranche of the new Growth
investment in "AI Company II"¹, a business that provides high-quality data
curation services for generative AI models and application developers, as
agreed when the initial investment was made earlier this year.

 ¹Actual name not disclosed due to confidentiality.

Top 10

The Company's top 10 holdings as of 30 September 2024 compared with the
respective value and percentage weighting as of 30 June 2024.

 Holding                 Strategy  Fair value as of 30 Jun 24 (£m)   % of NAV  Fair value as of 30 Sep 24 (£m)   % of NAV
 Atom Bank               Growth    23.1                              13.3      23.1                              14.0
 Revolut                 Growth    8.7                               5.0       11.9                              7.2
 Salica ET Fund          Growth    10.6                              6.1       10.2                              6.1
 Back Market             Growth    8.6                               5.0       8.5                               5.1
 Nexeon                  Venture   8.2                               4.7       8.2                               5.0
 AgroStar                Growth    7.9                               4.5       7.9                               4.8
 AI Company II           Growth    5.7                               3.2       7.5                               4.5
 Federated Wireless      Venture   5.4                               3.1       5.1                               3.1
 Autolus Therapeutics    Public    4.6                               2.6       4.5                                     2.7
 Oxford Nanopore         Public    10.2                              5.8       4.4                               2.7
 Cash & equivalents                30.1                              17.3      29.2                              17.7

 

Continuation Vote

The Company has committed to hold a continuation vote at its 2025 Annual
General Meeting, which is currently scheduled for May 2025. The Board has
determined, following a shareholder consultation exercise, to bring forward
the continuation vote in order to provide clarity on the future of the Company
at the earliest opportunity. The Company will make no further new investments
pending the outcome of this continuation vote, although further investment in
existing holdings is permitted, subject to Board approval.  If the
continuation vote does not pass, it is proposed that the Company will enter
into managed wind-down with any cash proceeds from realisations being returned
to shareholders over time. Any managed wind-down will reflect the illiquid
nature of the portfolio, with realisations being made at an appropriate time
in the life cycle of each investment in order to maximise returns for
shareholders. It is expected that a circular will be posted to shareholders in
January 2025, containing further details of the continuation vote and the
nature of any managed wind down, should the continuation vote not pass.

Outlook

Over the past quarter, the Portfolio Manager has continued to make
realisations which has placed the Company with a healthy cash and money market
funds balance.

Despite facing some short-term headwinds, which are to be expected with
long-term venture capital investing in early-stage companies, the Portfolio
Manager is confident in the outlook of the new investment portfolio that has
started to take shape.

The result of the continuation vote to be held shortly will provide clarity
over the future of the Company and enable the Portfolio Manager either: (i) to
use the Company's available resources to continue to build a diverse portfolio
of private investments; or (ii) to focus on managing the existing portfolio
with a view to maximising the returns for shareholders and returning capital
over time.

Past performance is not a guide to future performance and may not be repeated.
The value of investments and the income from them may go down as well as up
and investors may not get back the amounts originally invested. The securities
shown above are for illustrative purposes only and are not to be considered a
recommendation to buy or sell.

Enquiries:

Schroder Investment Management Limited

   Katherine Fyfe (Company Secretary)          0207 658 3136
   Charlotte Banks (Press)                     0207 658 9063
   John Spedding (Head of Investment Trusts)   0207 658 3206

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRFFFFLFLLVIIS